---
schema_version: "secwatch.filing_event.v1"
accession: "0001699031-25-000110"
form_type: "8-K"
ticker: "GRAL"
cik: "0001699031"
company_name: "GRAIL, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:31:01.192177+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GRAIL Q1 revenue $31.8M (+19% YoY); Galleri U.S. revenue $28.7M (+22%); net loss improves

## Summary
- Total revenue $31.8M, up 19% YoY; U.S. Galleri revenue $28.7M, up 22% YoY.
- Net loss $106.2M, improvement of $112.7M or 51% YoY; adjusted EBITDA -$98.7M.
- Positive top-line results from NHS-Galleri trial; cash $677.9M provides runway into 2028.
- Over 37,000 Galleri tests completed in Q1 2025; company focused on cost efficiency.

## SEC filing metadata
- accession: 0001699031-25-000110
- form_type: 8-K
- ticker: GRAL
- cik: 0001699031
- company_name: GRAIL, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699031/000169903125000110/0001699031-25-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699031/000169903125000110/gral-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001699031-25-000110
- JSON: https://secwatch.observer/filing/0001699031-25-000110.json
- Plain text: https://secwatch.observer/filing/0001699031-25-000110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.